Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTRALS phase 2 study of VHB937 in amyotrophic lateral sclerosis
CTR20251516Phase 2Active
- Sponsor
- Novartis
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of VHB937 in amyotrophic lateral sclerosis (ALS), sponsored by Novartis. Started Jul 2025; status: active.
02
Drugs
VHB937
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on CTR20251516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251516.